<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884350</url>
  </required_header>
  <id_info>
    <org_study_id>CV185-220</org_study_id>
    <secondary_id>2013-000055-41</secondary_id>
    <nct_id>NCT01884350</nct_id>
  </id_info>
  <brief_title>Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)</brief_title>
  <acronym>AEGEAN</acronym>
  <official_title>Assessment of an Education and Guidance Programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study purpose is to assess the impact of an educational program on patient adherence in
      patients taking Apixaban for SPAF at 24 weeks
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SPAF=Stroke Prevention in Atrial Fibrillation

      ISTH=International Society on Thrombosis and Hemostasis

      Primary Purpose: Other: To measure adherence to the study medication using an electronic
      monitoring device over the first 24 weeks on study medication
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2013</start_date>
  <completion_date type="Actual">January 20, 2016</completion_date>
  <primary_completion_date type="Actual">January 20, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen</measure>
    <time_frame>Day 1 up to week 24</time_frame>
    <description>The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence *100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks</measure>
    <time_frame>Day 1 to Week 12, Week 12 to Week 24</time_frame>
    <description>The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence *100 / total number of eligible days for the time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period</measure>
    <time_frame>Week 24 to Week 48</time_frame>
    <description>The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence *100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks</measure>
    <time_frame>Week 24</time_frame>
    <description>Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value &lt;= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value &lt;= 0.2). Odds ratios are presented for predictors of non-adherence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death</measure>
    <time_frame>Day 1 up to week 24</time_frame>
    <description>AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death</measure>
    <time_frame>Week 24 up to Week 48</time_frame>
    <description>Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1217</enrollment>
  <condition>Non-valvular Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Arm 1: Apixaban (Primary SOC information)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Primary Standard of Care (SOC) information</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Apixaban (Additional Educational Program)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and Additional Educational Program</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <arm_group_label>Arm 1: Apixaban (Primary SOC information)</arm_group_label>
    <arm_group_label>Arm 2: Apixaban (Additional Educational Program)</arm_group_label>
    <other_name>Eliquis</other_name>
    <other_name>BMS-562247</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with diagnosed non-valvular Atrial Fibrillation (AF) or atrial flutter
             (documented by 12-lead electrocardiogram (ECG) or Holter recording) and eligible for
             oral anticoagulant (OAC) therapy

          2. Presence of at least one of the following risk factors for stroke:

             Prior stroke or transient ischaemic attack (TIA)

               -  Age ≥75 years

               -  Hypertension

               -  Diabetes mellitus

               -  Symptomatic heart failure [New York Heart Association (NYHA) Class ≥II]

          3. Must be able to self-administer treatment

          4. Either Vitamin K antagonists (VKA) treated or VKA naive. Patients treated with VKA
             should have received the VKA treatment for ≥3 months. VKA naïve patients should not
             have received VKA treatment for more than 30 days within the last 12 months. Patients
             who are not described by either of the above criteria are not eligible for the study

          5. Patients previously treated with acetylsalicylic acid (ASA) for stroke prevention are
             allowed (and will switch to Apixaban)

          6. Patients with screening mini-mental state examination (MMSE) more than 24

          7. Subject Re-enrollment: This study does not permit the re-enrollment of a subject that
             has discontinued the study as a pre-treatment failure

        Age and Reproductive Status:

          -  i) Men and women ≥18 years of age

          -  ii) Women of childbearing potential (WOCBP) must use method(s) of contraception based
             on the tables in protocol. WOCBP must have a negative serum or urine pregnancy test
             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to the
             start of study medication

          -  iv) Women must not be breastfeeding

          -  v) Men who are sexually active with women of childbearing potential (WOCBP) must use
             any contraceptive method with a failure rate of less than 1% per year

          -  vi) Women who are not of childbearing potential (ie, who are postmenopausal or
             surgically sterile); and azoospermic men do not require contraception

        Exclusion Criteria:

          1. Target Disease Exceptions:

               1. Atrial fibrillation or flutter due to reversible causes (e.g. thyrotoxicosis,
                  pericarditis)

               2. Clinically significant (moderate or severe) mitral stenosis

               3. Cardiac valvular disease requiring surgery

               4. Planned major surgery or/and invasive procedure and/or atrial fibrillation or
                  flutter, ablation procedure and/or cardioversion

               5. Patients receiving Rivaroxaban, Dabigatran or Apixaban

          2. Medical History and Concurrent Diseases:

               1. Conditions other than atrial fibrillation that require chronic anticoagulation
                  (e.g., prosthetic mechanical heart valve, venous thromboembolism; also see
                  Section 3.4, Concomitant Treatments)

               2. Patient with serious bleeding in the last 6 months or with a lesion or condition
                  at high risk of bleeding such as:

                    -  Active peptic ulcer disease, current or recent gastrointestinal ulceration

                    -  Known or suspected esophageal varices

                    -  Recent ischemic stroke (within 7 days)

                    -  Recent brain or spinal injury or intracranial hemorrhage

                    -  Recent brain, spinal or ophthalmic surgery

                    -  Arteriovenous malformations

                    -  Vascular aneurysms

                    -  Major intraspinal or intracerebral vascular abnormalities

                    -  Documented hemorrhagic tendencies or blood dyscrasias

                    -  Presence of malignant neoplasms at high risk of bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Antwerpen</city>
        <zip>2060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bonheiden</city>
        <zip>2820</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Braine-l'alleud</city>
        <zip>1420</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gilly</city>
        <zip>6060</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hasselt</city>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ronse</city>
        <zip>9600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Woluwe- Saint Lambert</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yvoir</city>
        <zip>5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yvoir</city>
        <zip>B-5530</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Etienne</city>
        <state>Cedex 2</state>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Abbeville</city>
        <zip>80142</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Avignon Cedex 9</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Avignon</city>
        <zip>84000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bayonne Cedex</city>
        <zip>64109</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bayonne</city>
        <zip>64100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Beziers Cedex</city>
        <zip>34525</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bobigny</city>
        <zip>93009</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux</city>
        <zip>33000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Boulogne-billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bron</city>
        <zip>69677</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cambrai</city>
        <zip>59407</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chambray-les- Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chartes</city>
        <zip>28108</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chatellerault</city>
        <zip>86106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cholet</city>
        <zip>49309</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Colombes</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91106</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Creteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dijon Cedex</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grenoble Cedex 09</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grenoble Cedex 9</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Haguenau Cedex</city>
        <zip>67502</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>La Rochelle Cedex</city>
        <zip>17019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille Cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Longjumeau</city>
        <zip>91164</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille Cedex 20</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montfermeil</city>
        <zip>93370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier</city>
        <zip>34000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nantes Cedex 2</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Neuilly Sur Seine</city>
        <zip>92523</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice</city>
        <zip>06105</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nimes Cedex 9</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Orleans Cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex 14</city>
        <zip>75674</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris Cedex</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pau Universite Cedex</city>
        <zip>64046</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Plan de Cuques</city>
        <zip>13380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rennes Cedex 9</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint Denis</city>
        <zip>93207</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Salouel</city>
        <zip>80480</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sete</city>
        <zip>34200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St. Benoit</city>
        <zip>86280</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg</city>
        <zip>67090</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thionville</city>
        <zip>57100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Thonon Les Bains</city>
        <zip>74203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse Cedex 3</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toulouse</city>
        <zip>31054</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tourcoing</city>
        <zip>59208</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valence</city>
        <zip>26000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valenciennes Cedex</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vesoul</city>
        <zip>70014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wardenburg</city>
        <zip>26203</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Spaichingen</city>
        <state>Baden-wurttembe</state>
        <zip>78549</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krombach</city>
        <state>Bayern</state>
        <zip>63829</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Augsburg</city>
        <zip>86159</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aurich</city>
        <zip>26603</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bad Homburg</city>
        <zip>61348</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Balingen</city>
        <zip>72336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bamberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berin</city>
        <zip>10559</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10367</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>10789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>12351</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>12524</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Berlin</city>
        <zip>13405</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chemnitz</city>
        <zip>09122</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Deggingen</city>
        <zip>73326</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dillingen</city>
        <zip>66763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dresden</city>
        <zip>01277</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Erfurt</city>
        <zip>99084</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Essen</city>
        <zip>45138</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Floersheim</city>
        <zip>65439</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Friedberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gars/Inn</city>
        <zip>83536</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Gottingen</city>
        <zip>37073</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Grossheirath Rossbach</city>
        <zip>96269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>22299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamburg</city>
        <zip>22459</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hassloch</city>
        <zip>67454</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Heidenau</city>
        <zip>01809</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kassel</city>
        <zip>34117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kelkheim</city>
        <zip>65779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kuenzing</city>
        <zip>94550</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Langestrasse</city>
        <zip>04910</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leipzig</city>
        <zip>04104</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lollar</city>
        <zip>35457</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71634</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mammendorf</city>
        <zip>82291</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mannheim</city>
        <zip>68161</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mannheim</city>
        <zip>68163</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Markkleeberg</city>
        <zip>04416</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Munster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Myen</city>
        <zip>56727</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Neukirchen</city>
        <zip>66539</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Neunirchen</city>
        <zip>66540</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Northeim</city>
        <zip>37154</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Obermichelbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Papenburg</city>
        <zip>D-26871</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pirna</city>
        <zip>01796</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Riesa</city>
        <zip>D-01587</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rodgau</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Rotenburg /fulda</city>
        <zip>36199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sinzheim</city>
        <zip>76547</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stockach</city>
        <zip>78333</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Unterschneidheim</city>
        <zip>73485</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wallerfing</city>
        <zip>94574</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wangen</city>
        <zip>88239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Weissenhorn</city>
        <zip>89264</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wermsdorf</city>
        <zip>04779</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wetzlar</city>
        <zip>35584</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Weyhe</city>
        <zip>28844</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winsen</city>
        <zip>21423</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Arezzo</city>
        <zip>52100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bologna</city>
        <zip>40133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Castelfranco Veneto (tv)</city>
        <zip>31033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cremona</city>
        <zip>26100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Firenze</city>
        <zip>50122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Firenze</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Foggia</city>
        <zip>71100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Mestre</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Milano</city>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Naples</city>
        <zip>80123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Perugia</city>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Piacenza</city>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Daniele Del Friuli(udine)</city>
        <zip>33038</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Torino</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Treviso</city>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Varese</city>
        <zip>21100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vicenza</city>
        <zip>36100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Vimercate</city>
        <zip>20059</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Viterbo</city>
        <zip>01100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>San Sebastian De Los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Aldaya</city>
        <zip>46960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Alicante</city>
        <zip>03015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Galdacano</city>
        <zip>48960</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28033</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Murcia</city>
        <zip>30120 El Palmar</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oviedo</city>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago De Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tarragona</city>
        <zip>43007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Viladecans</city>
        <zip>08840</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fribourg</city>
        <state>Canton</state>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lugano</city>
        <state>Ticino</state>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bern 4</city>
        <zip>3004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zurich</city>
        <zip>8032</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Zurich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Craigavon</city>
        <state>Armagh</state>
        <zip>BT63 5QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Darlington</city>
        <state>County Durham</state>
        <zip>DL3 8SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Exeter</city>
        <state>Devon</state>
        <zip>EX2 5DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bournemouth</city>
        <state>Dorset</state>
        <zip>BH7 7DW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poole</city>
        <state>Dorset</state>
        <zip>BH15 2JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westcliff-on-sea</city>
        <state>Essex</state>
        <zip>SS0 0RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ashford</city>
        <state>Kent</state>
        <zip>TN24 0LZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Airdrie</city>
        <state>Lancashire</state>
        <zip>ML6 OJS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Liverpool</city>
        <state>Merseyside</state>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Stoke-on-trent</city>
        <state>Staffordshire</state>
        <zip>ST4 6QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Birmingham</city>
        <state>WEST Midlands</state>
        <zip>B18 7QH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Dudley</city>
        <state>WEST Midlands</state>
        <zip>DY1 2HQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hereford</city>
        <zip>HR12ER</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oldham</city>
        <zip>OL12JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Somerset</city>
        <zip>BA21 4AT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tauton</city>
        <zip>TA1 5DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.bms.com/researchers-and-partners/investigator-inquiry-form.html</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 13, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <results_first_submitted>September 12, 2017</results_first_submitted>
  <results_first_submitted_qc>July 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 19, 2019</results_first_posted>
  <last_update_submitted>July 10, 2019</last_update_submitted>
  <last_update_submitted_qc>July 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apixaban</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1217 participants were enrolled, 1162 randomized (583 Primary SOC,579 AEP). 55 were enrolled but not randomized. Of the 55, 13 no longer met study criteria, 13 withdrew consent, 3 lost to follow-up, 10 other and 16 unknown.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Apixaban (Primary SOC)</title>
          <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
        </group>
        <group group_id="P2">
          <title>Apixaban (Additional Educational Program)</title>
          <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
        </group>
        <group group_id="P3">
          <title>Apixaban (Secondary SOC)</title>
          <description>Participants were originally in the Apixaban (AEP) arm and treated with Apixaban 2.5 mg or 5 mg by mouth twice daily and Additional Educational Program (AEP) for the first 24 weeks. After the initial 24-week primary endpoint period participants stopped receiving AEP and were transferred from Apixaban (AEP) arm, stopped the Additional Educational Program (AEP), and switched to the Standard of Care (SOC) information for an additional 24 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Efficacy Analysis Set (24 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="583"/>
                <participants group_id="P2" count="579"/>
                <participants group_id="P3" count="0">Participants were not randomized to this arm until after initial 24-week period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="604"/>
                <participants group_id="P2" count="558"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="529"/>
                <participants group_id="P2" count="525"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="54"/>
                <participants group_id="P2" count="54"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Drug Interruption &gt;30 Consecutive Days</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion/exclusion criterion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Helping Hand not used</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Helping Hand not used, treatment taken</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical reason</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Primary Efficacy Analysis Set (48 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="583"/>
                <participants group_id="P2" count="263">After 24 weeks participants were randomized to continue AEP or stop AEP and revert to SOC.</participants>
                <participants group_id="P3" count="261">After 24 weeks participants were randomized to continue AEP or stop AEP and revert to SOC.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="604"/>
                <participants group_id="P2" count="308"/>
                <participants group_id="P3" count="223"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="503"/>
                <participants group_id="P2" count="250"/>
                <participants group_id="P3" count="250"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Subject Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Drug Interruption &gt;30 Consecutive Days</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Helping Hand not used</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Helping Hand not used, treatment taken</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Medical reason</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Inclusion / Exclusion Criterion</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Primary Efficacy Analysis Set (24 week)</population>
      <group_list>
        <group group_id="B1">
          <title>Apixaban (Primary SOC Information)</title>
          <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
        </group>
        <group group_id="B2">
          <title>Apixaban (Additional Educational Program)</title>
          <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="583"/>
            <count group_id="B2" value="579"/>
            <count group_id="B3" value="1162"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.6" spread="8.94"/>
                    <measurement group_id="B2" value="73.1" spread="9.05"/>
                    <measurement group_id="B3" value="72.9" spread="9.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="86"/>
                    <measurement group_id="B2" value="77"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
                <category>
                  <title>64-74 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="221"/>
                    <measurement group_id="B2" value="220"/>
                    <measurement group_id="B3" value="441"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=75 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="276"/>
                    <measurement group_id="B2" value="282"/>
                    <measurement group_id="B3" value="558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="232"/>
                    <measurement group_id="B2" value="234"/>
                    <measurement group_id="B3" value="466"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="351"/>
                    <measurement group_id="B2" value="345"/>
                    <measurement group_id="B3" value="696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen</title>
        <description>The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence *100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.</description>
        <time_frame>Day 1 up to week 24</time_frame>
        <population>Primary efficacy analysis set (Week 24), which consists of all randomized participants</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban (Primary SOC Information)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban (Additional Educational Program)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen</title>
          <description>The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence *100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence up to 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 24 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.</description>
          <population>Primary efficacy analysis set (Week 24), which consists of all randomized participants</population>
          <units>percentage of days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
                <count group_id="O2" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.64" spread="17.143"/>
                    <measurement group_id="O2" value="91.88" spread="16.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8117</p_value>
            <p_value_desc>P-value (two-sided) corresponds to the two-sample t-tests for difference in percentage of adherence at Week 24</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Difference in Percentage</param_type>
            <param_value>-0.24</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.18</ci_lower_limit>
            <ci_upper_limit>1.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks</title>
        <description>The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence *100 / total number of eligible days for the time period.</description>
        <time_frame>Day 1 to Week 12, Week 12 to Week 24</time_frame>
        <population>Primary efficacy analysis set (Week 24) with available data at both study days 85 and 169</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban (Primary SOC Information)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban (Additional Educational Program)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 12 to 24 Weeks Period Compared With During the First 12 Weeks</title>
          <description>The mean adherence to apixaban treatment during the first 24 weeks was measured between the standard of care (SOC) information and Additional Education Program (AEP) arms and expressed as a percentage. Adherence to Apixaban = number of units of adherence *100 / total number of eligible days for the time period.</description>
          <population>Primary efficacy analysis set (Week 24) with available data at both study days 85 and 169</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="583"/>
                <count group_id="O2" value="579"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1 to Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="525"/>
                    <count group_id="O2" value="527"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.7" spread="14.18"/>
                    <measurement group_id="O2" value="93.0" spread="15.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 to Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="525"/>
                    <count group_id="O2" value="527"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.3" spread="20.64"/>
                    <measurement group_id="O2" value="90.9" spread="18.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Percent adherence at 12 Weeks v. Percent adherence at 24 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is from a paired t-test comparing percent adherence at 12 and 24 Weeks. Only participants with available data at both Study Days 85 and 169 are included.</p_value_desc>
            <method>paired t-test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent adherence at 12 Weeks v. Percent adherence at 24 Weeks</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <p_value_desc>P-value is from a paired t-test comparing percent adherence at 12 and 24 Weeks. Only participants with available data at both Study Days 85 and 169 are included.</p_value_desc>
            <method>paired t-test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period</title>
        <description>The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence *100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.</description>
        <time_frame>Week 24 to Week 48</time_frame>
        <population>All treated participants in 24 to 48-week period. Participants that had not been using the EMD consistently throughout the study were excluded from the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban (Primary SOC Information)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban (Additional Educational Program)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
          </group>
          <group group_id="O3">
            <title>Apixaban (Secondary SOC)</title>
            <description>Participants were originally in the Apixaban (AEP) arm and treated with Apixaban 2.5 mg or 5 mg by mouth twice daily and Additional Educational Program (AEP) for the first 24 weeks. After the initial 24-week primary endpoint period participants stopped receiving AEP and were transferred from Apixaban (AEP) arm, stopped the Additional Educational Program (AEP), and switched to the Standard of Care (SOC) information for an additional 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Days With a Correct Execution of the Apixaban Dosing Regimen During the 24 to 48 Weeks Period</title>
          <description>The mean percentage of days which participants maintained adherence to apixaban treatment was measured for each arm. Adherence to apixaban = number of units of adherence *100 / total number of eligible days for the time period from first dose date, up to 169 days. Unit of adherence: A 24-hour window where the treatment is taken as prescribed, ie, 1 tablet (5 mg or 2.5 mg, as appropriate) 2 times a day. If only one dose is missed in 24-hours, it is still considered as a unit of adherence. Adherence over 24 weeks was calculated as the percentage of adherence units within that period. If a participant discontinued from the study before 48 weeks, the denominator time period was censored at the earlier of last dose date or discontinuation date for discontinuation due to reasons unrelated to participant adherence, such as withdrawn consent, or AE; otherwise, the period was censored at the minimum of 169 days and last dose date + 30 days.</description>
          <population>All treated participants in 24 to 48-week period. Participants that had not been using the EMD consistently throughout the study were excluded from the analysis.</population>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="510"/>
                <count group_id="O2" value="253"/>
                <count group_id="O3" value="254"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.59" spread="22.921"/>
                    <measurement group_id="O2" value="88.41" spread="22.148"/>
                    <measurement group_id="O3" value="87.51" spread="21.125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>F-test p-value is obtained from the one-way ANOVA model</non_inferiority_desc>
            <p_value>0.8707</p_value>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6399</p_value>
            <p_value_desc>P-values are obtained from the Cochran t-test for pairwise comparison between groups (two-sided).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.88</ci_lower_limit>
            <ci_upper_limit>4.68</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9616</p_value>
            <p_value_desc>P-values are obtained from the Cochran t-test for pairwise comparison between groups (two-sided).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.45</ci_lower_limit>
            <ci_upper_limit>3.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6341</p_value>
            <p_value_desc>P-values are obtained from the Cochran t-test for pairwise comparison between groups (two-sided).</p_value_desc>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.60</ci_lower_limit>
            <ci_upper_limit>4.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks</title>
        <description>Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value &lt;= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value &lt;= 0.2). Odds ratios are presented for predictors of non-adherence.</description>
        <time_frame>Week 24</time_frame>
        <population>Primary Efficacy Set participants with evaluable data at week 24</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban (Primary SOC Information)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban (Additional Educational Program)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-adherence Predictors of 20% or More (vs. at Least 80% Adherence) at 24 Weeks</title>
          <description>Logit analyses were conducted on the Primary Efficacy Set to identify non-adherence predictors of 20% or more (vs. at least 80% adherence) at 24 weeks. In the Primary SOC group, alcohol use, Mini-Mental State Evaluation (MMSE) score, UK standard occupational classification, and type of atrial fibrillation were retained in the model (p-value &lt;= 0.2). In the Additional Educational Program group, alcohol use, type of atrial fibrillation, age and Vitamin K Antagonists (VKA) status were retained in the model (p-value &lt;= 0.2). Odds ratios are presented for predictors of non-adherence.</description>
          <population>Primary Efficacy Set participants with evaluable data at week 24</population>
          <units>Odds ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="557"/>
                <count group_id="O2" value="560"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;=2 Alcoholic Drink/Day Average vs None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.251" lower_limit="0.691" upper_limit="2.265"/>
                    <measurement group_id="O2" value="0.994" lower_limit="0.558" upper_limit="1.682"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=3 Alcoholic Drink/Day Average vs None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.268" lower_limit="1.226" upper_limit="14.859"/>
                    <measurement group_id="O2" value="3.782" lower_limit="0.884" upper_limit="16.178"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mini-mental state examination score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.808" lower_limit="0.686" upper_limit="0.952"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Higher mgmt., adm. and professional jobs vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.827" lower_limit="0.136" upper_limit="5.033"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Higher professional occupations vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.898" lower_limit="0.197" upper_limit="4.091"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intermediate occupations vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.230" lower_limit="0.401" upper_limit="3.769"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Large employers and mgmt. and adm. jobs vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.823" lower_limit="0.412" upper_limit="19.338"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower mgmt., adm. and professional jobs vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.948" lower_limit="0.256" upper_limit="3.515"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower supervisory and tech. occupations vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.587" lower_limit="1.008" upper_limit="12.766"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Never worked and long-term unemployed vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.289" lower_limit="0.419" upper_limit="3.962"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Routine occupations vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.508" lower_limit="0.181" upper_limit="1.425"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Semi-routine occupations vs UKSOC1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.450" lower_limit="0.083" upper_limit="2.453"/>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal vs Persistant Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.626" lower_limit="0.766" upper_limit="3.453"/>
                    <measurement group_id="O2" value="1.911" lower_limit="0.940" upper_limit="3.885"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent vs Persistant Atrial Fibrillation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.560" lower_limit="1.152" upper_limit="5.688"/>
                    <measurement group_id="O2" value="1.846" lower_limit="0.819" upper_limit="4.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VKA Naïve vs Non-Naïve</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Not retained in model (p-value &gt; 0.2)</measurement>
                    <measurement group_id="O2" value="1.686" lower_limit="0.932" upper_limit="3.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1924</p_value>
            <p_value_desc>&lt;=2 Drink/Day Average vs None</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0305</p_value>
            <p_value_desc>&gt;=3 Drink/Day Average vs None</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0107</p_value>
            <p_value_desc>Mini-mental state examination score</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6982</p_value>
            <p_value_desc>Higher managerial, administrative and professional occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7277</p_value>
            <p_value_desc>Higher professional occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7581</p_value>
            <p_value_desc>Intermediate occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2328</p_value>
            <p_value_desc>Large employers and higher managerial and adm. occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7507</p_value>
            <p_value_desc>Lower managerial, administrative and professional occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0091</p_value>
            <p_value_desc>Lower supervisory and technical occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6730</p_value>
            <p_value_desc>Never worked and long-term unemployed vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0117</p_value>
            <p_value_desc>Routine occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1910</p_value>
            <p_value_desc>Semi-routine occupations vs UKSOC1</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9559</p_value>
            <p_value_desc>Paroxysmal vs Persistent Atrial Fibrillation</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0264</p_value>
            <p_value_desc>Permanent vs Persistant Atrial Fibrillation</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1087</p_value>
            <p_value_desc>&lt;=2 Drink/Day Average vs None</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0679</p_value>
            <p_value_desc>&gt;=3 Drink/Day Average vs None</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2128</p_value>
            <p_value_desc>Paroxysmal vs Persistant Atrial Fibrillation</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3739</p_value>
            <p_value_desc>Permanent vs Persistant Atrial Fibrillation</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.843</p_value>
            <p_value_desc>VKA status: Naive vs. Non-Naive</p_value_desc>
            <method>Wald Chi-square test</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death</title>
        <description>AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
        <time_frame>Day 1 up to week 24</time_frame>
        <population>All randomized participants. Participants in the safety analysis set were categorized according to the counseling actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban (Primary SOC Information)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban (Additional Educational Program)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death</title>
          <description>AEs with onset date from day 1 through week 24 are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
          <population>All randomized participants. Participants in the safety analysis set were categorized according to the counseling actually received</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="604"/>
                <count group_id="O2" value="558"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death</title>
        <description>Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
        <time_frame>Week 24 up to Week 48</time_frame>
        <population>All randomized participants remaining in the study after week 24. All randomized participants. Participants in the safety analysis set were categorized according to the counseling actually received</population>
        <group_list>
          <group group_id="O1">
            <title>Apixaban (Primary SOC Information)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received Primary Standard of Care (SOC) information.</description>
          </group>
          <group group_id="O2">
            <title>Apixaban (Additional Educational Program)</title>
            <description>Participants were treated with Apixaban 2.5 mg or 5 mg by mouth twice daily for 48 weeks and received the Additional Educational Program (AEP). After the initial 24-week primary endpoint period, participants in the AEP group were randomized 1:1 to continue receiving AEP or stop receiving AEP and revert to Standard of Care (SOC) information via the Apixaban (Secondary SOC) group.</description>
          </group>
          <group group_id="O3">
            <title>Apixaban (Secondary SOC)</title>
            <description>Participants were originally in the Apixaban (AEP) arm and treated with Apixaban 2.5 mg or 5 mg by mouth twice daily and Additional Educational Program (AEP) for the first 24 weeks. After the initial 24-week primary endpoint period participants stopped receiving AEP and were transferred from Apixaban (AEP) arm, stopped the Additional Educational Program (AEP), and switched to the Standard of Care (SOC) information for an additional 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAEs), Drug Related Adverse Events (AE), AE Leading to Discontinuation, and Death</title>
          <description>Adverse events with onset date after 24 weeks are included in this summary. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization. Treatment-related=having certain, probable, possible, or missing relationship to study drug.</description>
          <population>All randomized participants remaining in the study after week 24. All randomized participants. Participants in the safety analysis set were categorized according to the counseling actually received</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="604"/>
                <count group_id="O2" value="308"/>
                <count group_id="O3" value="223"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug related AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AE leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From date of first dose to date of last dose plus 30 days</time_frame>
      <desc>All randomized participants were analyzed. Participants in the safety analysis set were categorized according to the counseling actually received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Primary SOC (Period 1)</title>
          <description>Apixaban 2.5 mg or 5 mg by mouth twice daily for 24 weeks and Primary SOC information.</description>
        </group>
        <group group_id="E2">
          <title>Continued Additional Educational Program (CAEP) (Period 2)</title>
          <description>Subjects enrolled in AEP program during the first 24 weeks continued receiving AEP program up to 48 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Secondary SOC (Period 2)</title>
          <description>Subjects who received AEP for 24 weeks then revert to SOC after the second randomization.</description>
        </group>
        <group group_id="E4">
          <title>Additional Educational Program (Period 1)</title>
          <description>Apixaban 2.5 mg or 5 mg by mouth twice daily for 24 weeks and Additional Educational Program.</description>
        </group>
        <group group_id="E5">
          <title>Primary SOC (Period 2)</title>
          <description>Subjects who received Apixaban 2.5 mg or 5 mg by mouth twice daily for initial 24 weeks and Primary SOC information continued for a period 48 Weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="79" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypofibrinogenaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Spontaneous haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Atrial tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Atrioventricular block</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac valve disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Drug intolerance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Device malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Implant site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Multi-Organ failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Sudden death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Infective exacerbation of chronic obstructive airways disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Chest injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspiration breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Blood test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Biopsy lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac stress test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Mobility decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Invasive lobular breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Metastatic neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Tongue neoplasm malignant stage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Basal ganglia infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cerebellar haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cerebral haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Post stroke seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Radicular syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cystitis haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Breast cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Acute pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Elderly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Arthroscopic surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Breast conserving surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cancer surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker battery replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardiac resynchronisation therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Cardioversion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Corneal transplant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Heart valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Gastrointestinal endoscopic therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Lung lobectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Mitral valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Scar excision</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aneurysm ruptured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="604"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="308"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="223"/>
                <counts group_id="E4" subjects_affected="46" subjects_at_risk="558"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="604"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period ≤60 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb</organization>
      <email>Clinical.Trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

